Cover Image
市場調查報告書

PharmaPoint:神經病變性疼痛 - 現在·未來市場參與企業

PharmaPoint: Neuropathic Pain - Current and Future Players

出版商 GlobalData 商品編碼 302384
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:神經病變性疼痛 - 現在·未來市場參與企業 PharmaPoint: Neuropathic Pain - Current and Future Players
出版日期: 2014年04月30日 內容資訊: 英文 51 Pages
簡介

本報告提供全球神經病變性疼痛相關市場上的現有企業及新加入企業相關分析,提供今後的整體市場預測和促進·阻礙因素,現在·未來的競爭方案,再加上主要企業簡介(營業內容,策略,業績·財務實際成果,競爭力)等調查資料·考察,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

  • 本報告概要
  • 相關調查

第3章 市場預測

  • 全球市場
    • 未來預測
    • 市場促進·阻礙因素:全世界的課題

第4章 現在·未來市場參與企業

  • 概要
  • 企業策略的趨勢
  • 企業簡介
    • Pfizer
    • Eli Lilly
    • Grunenthal
    • Endo Health Solutions
    • Janssen Pharmaceuticals
    • 第一三共
    • Convergence Pharmaceuticals

第5章 附錄

圖表一覽

目錄
Product Code: GDHC1034FPR

GlobalData has released its pharma report, "PharmaPoint: Neuropathic Pain - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Neuropathic Pain Market. The report identifies and analyses the key companies shaping and driving the global Neuropathic Pain market. The report provides insight into the competitive Neuropathic Pain landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Neuropathic Pain
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of the Neuropathic Pain sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving the Neuropathic Pain Market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Neuropathic Pain market landscape? Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers - Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Company Profiles
    • 4.3.1. Pfizer
    • 4.3.2. Eli Lilly
    • 4.3.3. Grunenthal
    • 4.3.4. Endo Health Solutions
    • 4.3.5. Janssen Pharmaceuticals
    • 4.3.6. Daiichi Sankyo
    • 4.3.7. Convergence Pharmaceuticals

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Diagnosed PDN, PHN, and TN Patients
    • 5.4.2. Percent Drug-Treated Patients
    • 5.4.3. General Pricing Assumptions
    • 5.4.4. Generic Erosion
  • 5.5. Physicians and Specialists Included in This Study
  • 5.6. About the Authors
    • 5.6.1. Author
    • 5.6.2. Global Head of Healthcare
  • 5.7. About GlobalData
  • 5.8. Disclaimer

List of Tables

  • Table 1: Global Sales Forecasts ($) for NP, 2012-2022
  • Table 2: Global Sales Forecasts ($) for PDN, 2012-2022
  • Table 3: Global Sales Forecasts ($) for PHN, 2012-2022
  • Table 4: Global Sales Forecasts ($) for TN, 2012-2022
  • Table 5: NP Market - Drivers and Barriers, 2012-2022
  • Table 6: Key Companies in the NP Market, 2014
  • Table 7: Pfizer's NP Portfolio Assessment, 2014
  • Table 8: Pfizer SWOT Analysis, 2013
  • Table 9: Eli Lilly's NP Portfolio Assessment, 2013
  • Table 10: Eli Lilly SWOT Analysis, 2013
  • Table 11: Grunenthal's NP Portfolio Assessment, 2013
  • Table 12: Grunenthal SWOT Analysis, 2013
  • Table 13: Endo Health Solutions' NP Portfolio Assessment, 2013
  • Table 14: Endo Health Solutions SWOT Analysis, 2013
  • Table 15: Janssen Pharmaceuticals' NP Portfolio Assessment, 2013
  • Table 16: Janssen Pharmaceuticals SWOT Analysis, 2013
  • Table 17: Daiichi Sankyo's NP Portfolio Assessment, 2013
  • Table 18: Daiichi Sankyo SWOT Analysis, 2013
  • Table 19: Convergence Pharmaceuticals' NP Portfolio Assessment, 2013
  • Table 20: Convergence Pharmaceuticals SWOT Analysis, 2013

List of Figures

  • Figure 1: Global Sales for NP by Region, 2012-2022
  • Figure 2: Global Sales for PDN by Drug Class, 2012-2022
  • Figure 3: Global Sales for PHN by Drug Class, 2012-2022
  • Figure 4: Global Sales for TN by Drug Class, 2012-2022
  • Figure 5: Company Portfolio Gap Analysis in NP, 2012-2022
Back to Top